NEJM.org

Bluesky

@nejm.org

—Followers

—Following

0Posts Analyzed

Analyzed Posts (1)

NEJM.org

@nejm.orgJul 23, 2026

Among patients with multiple myeloma, 7-year overall survival with 2 years of lenalidomide therapy was similar to that with indefinite therapy. Adverse events and second cancers were more common with indefinite therapy. Full phase 3 ENDURANCE trial results: https://nej.md/3TlfOlb

Very strongView analysis